Does the media prefer PCVX or OCUL?

In the previous week, Vaxcyte had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 9 mentions for Vaxcyte and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.86 beat Vaxcyte's score of 0.38 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, QGEN or OCUL?

Qiagen has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.09 $424.88M $1.91 21.70 Ocular Therapeutix $51.95M 41.64 -$265.94M -$1.46 N/A

Does the media prefer QGEN or OCUL?

In the previous week, Qiagen had 10 more articles in the media than Ocular Therapeutix. MarketBeat recorded 14 mentions for Qiagen and 4 mentions for Ocular Therapeutix. Qiagen's average media sentiment score of 1.04 beat Ocular Therapeutix's score of 0.86 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OCUL or APGE?

In the previous week, Apogee Therapeutics had 6 more articles in the media than Ocular Therapeutix. MarketBeat recorded 10 mentions for Apogee Therapeutics and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.86 beat Apogee Therapeutics' score of 0.65 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OCUL or TGTX?

In the previous week, TG Therapeutics had 8 more articles in the media than Ocular Therapeutix. MarketBeat recorded 12 mentions for TG Therapeutics and 4 mentions for Ocular Therapeutix. TG Therapeutics' average media sentiment score of 0.89 beat Ocular Therapeutix's score of 0.86 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMVT or OCUL?

In the previous week, Immunovant had 9 more articles in the media than Ocular Therapeutix. MarketBeat recorded 13 mentions for Immunovant and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.86 beat Immunovant's score of 0.46 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ocular Therapeutix (OCUL) Competitors

$9.88 -0.32 (-3.14%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$9.93 +0.05 (+0.50%)

As of 07/13/2026 07:56 PM Eastern

Compare

OCUL vs. PCVX, QGEN, APGE, TGTX, and IMVT

Should you buy Ocular Therapeutix stock or one of its competitors? MarketBeat compares Ocular Therapeutix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocular Therapeutix include Vaxcyte (PCVX), Qiagen (QGEN), Apogee Therapeutics (APGE), TG Therapeutics (TGTX), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.

How does Ocular Therapeutix compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Vaxcyte had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 9 mentions for Vaxcyte and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.86 beat Vaxcyte's score of 0.38 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 50.80%. Ocular Therapeutix has a consensus target price of $25.11, indicating a potential upside of 154.16%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Vaxcyte has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Vaxcyte's return on equity of -32.51% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Ocular Therapeutix has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Ocular Therapeutix	$51.95M	41.64	-$265.94M	-$1.46	N/A

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Ocular Therapeutix beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Qiagen?

Qiagen (NYSE:QGEN) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Qiagen has a net margin of 19.16% compared to Ocular Therapeutix's net margin of -558.24%. Qiagen's return on equity of 14.40% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

70.0% of Qiagen shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Qiagen has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Qiagen has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.09	$424.88M	$1.91	21.70
Ocular Therapeutix	$51.95M	41.64	-$265.94M	-$1.46	N/A

In the previous week, Qiagen had 10 more articles in the media than Ocular Therapeutix. MarketBeat recorded 14 mentions for Qiagen and 4 mentions for Ocular Therapeutix. Qiagen's average media sentiment score of 1.04 beat Ocular Therapeutix's score of 0.86 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen presently has a consensus target price of $43.15, suggesting a potential upside of 4.11%. Ocular Therapeutix has a consensus target price of $25.11, suggesting a potential upside of 154.16%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Qiagen beats Ocular Therapeutix on 12 of the 17 factors compared between the two stocks.

How does Ocular Therapeutix compare to Apogee Therapeutics?

Ocular Therapeutix (NASDAQ:OCUL) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Ocular Therapeutix has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Apogee Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Apogee Therapeutics' return on equity of -32.64% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Ocular Therapeutix presently has a consensus target price of $25.11, suggesting a potential upside of 154.16%. Apogee Therapeutics has a consensus target price of $121.25, suggesting a potential downside of 9.39%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Apogee Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	41.64	-$265.94M	-$1.46	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

In the previous week, Apogee Therapeutics had 6 more articles in the media than Ocular Therapeutix. MarketBeat recorded 10 mentions for Apogee Therapeutics and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.86 beat Apogee Therapeutics' score of 0.65 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ocular Therapeutix and Apogee Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to TG Therapeutics?

Ocular Therapeutix (NASDAQ:OCUL) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, TG Therapeutics had 8 more articles in the media than Ocular Therapeutix. MarketBeat recorded 12 mentions for TG Therapeutics and 4 mentions for Ocular Therapeutix. TG Therapeutics' average media sentiment score of 0.89 beat Ocular Therapeutix's score of 0.86 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	41.64	-$265.94M	-$1.46	N/A
TG Therapeutics	$616.29M	13.66	$447.18M	$2.86	19.23

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ocular Therapeutix currently has a consensus target price of $25.11, indicating a potential upside of 154.16%. TG Therapeutics has a consensus target price of $53.33, indicating a potential downside of 3.05%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Ocular Therapeutix has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Ocular Therapeutix's net margin of -558.24%. TG Therapeutics' return on equity of 88.73% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
TG Therapeutics	65.95%	88.73%	43.44%

Summary

TG Therapeutics beats Ocular Therapeutix on 12 of the 17 factors compared between the two stocks.

How does Ocular Therapeutix compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, Immunovant had 9 more articles in the media than Ocular Therapeutix. MarketBeat recorded 13 mentions for Immunovant and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.86 beat Immunovant's score of 0.46 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Ocular Therapeutix's return on equity of -64.28% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Immunovant currently has a consensus target price of $39.70, indicating a potential upside of 2.58%. Ocular Therapeutix has a consensus target price of $25.11, indicating a potential upside of 154.16%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ocular Therapeutix has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Ocular Therapeutix	$51.95M	41.64	-$265.94M	-$1.46	N/A

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Summary

Ocular Therapeutix beats Immunovant on 13 of the 15 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCUL vs. The Competition

Export

Metric	Ocular Therapeutix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.23B	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-6.77	19.17	27.11	24.26
Price / Sales	41.64	838.79	587.92	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	3.22	4.22	10.75	6.29
Net Income	-$265.94M	$64.26M	$3.58B	$330.66M
7 Day Performance	-4.36%	-3.58%	-2.06%	-1.32%
1 Month Performance	10.51%	2.12%	3.32%	-0.64%
1 Year Performance	-12.33%	20.35%	26.35%	19.08%

Ocular Therapeutix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCUL Ocular Therapeutix	3.2082 of 5 stars	$9.88 -3.1%	$25.11 +154.2%	-10.4%	$2.23B	$51.95M	N/A	230
PCVX Vaxcyte	2.4739 of 5 stars	$56.96 -2.4%	$86.00 +51.0%	+58.7%	$8.43B	N/A	N/A	160
QGEN Qiagen	4.1549 of 5 stars	$39.15 -2.4%	$43.15 +10.2%	-18.2%	$8.26B	$2.09B	20.45	5,654	Positive News
APGE Apogee Therapeutics	1.851 of 5 stars	$133.50 +0.4%	$121.25 -9.2%	+250.9%	$8.23B	N/A	N/A	91	Short Interest Decrease
TGTX TG Therapeutics	3.1347 of 5 stars	$55.47 +4.1%	$58.60 +5.6%	+48.4%	$8.16B	$616.29M	19.40	290	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCUL) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocular Therapeutix (OCUL) Competitors

OCUL vs. PCVX, QGEN, APGE, TGTX, and IMVT

How does Ocular Therapeutix compare to Vaxcyte?

Summary

How does Ocular Therapeutix compare to Qiagen?

Summary

How does Ocular Therapeutix compare to Apogee Therapeutics?

Summary

How does Ocular Therapeutix compare to TG Therapeutics?

Summary

How does Ocular Therapeutix compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocular Therapeutix (OCUL) Competitors

OCUL vs. PCVX, QGEN, APGE, TGTX, and IMVT

How does Ocular Therapeutix compare to Vaxcyte?

Does the media prefer PCVX or OCUL?

Which has more risk and volatility, PCVX or OCUL?

Do analysts recommend PCVX or OCUL?

Is PCVX or OCUL more profitable?

Which has higher valuation & earnings, PCVX or OCUL?

Do insiders and institutionals believe in PCVX or OCUL?

Summary

How does Ocular Therapeutix compare to Qiagen?

Is QGEN or OCUL more profitable?

Do institutionals & insiders have more ownership in QGEN or OCUL?

Which has more risk & volatility, QGEN or OCUL?

Which has stronger valuation and earnings, QGEN or OCUL?

Does the media prefer QGEN or OCUL?

Do analysts rate QGEN or OCUL?

Summary

How does Ocular Therapeutix compare to Apogee Therapeutics?

Which has more risk and volatility, OCUL or APGE?

Is OCUL or APGE more profitable?

Do analysts rate OCUL or APGE?

Which has higher valuation and earnings, OCUL or APGE?

Does the media favor OCUL or APGE?

Do insiders & institutionals have more ownership in OCUL or APGE?

Summary

How does Ocular Therapeutix compare to TG Therapeutics?

Does the media favor OCUL or TGTX?

Which has preferable valuation and earnings, OCUL or TGTX?

Do insiders and institutionals believe in OCUL or TGTX?

Do analysts rate OCUL or TGTX?

Which has more risk & volatility, OCUL or TGTX?

Is OCUL or TGTX more profitable?

Summary

How does Ocular Therapeutix compare to Immunovant?

Does the media refer more to IMVT or OCUL?

Is IMVT or OCUL more profitable?

Do analysts rate IMVT or OCUL?

Do insiders and institutionals believe in IMVT or OCUL?

Which has higher valuation & earnings, IMVT or OCUL?

Which has more volatility and risk, IMVT or OCUL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools